Cargando…

Saporin, a Polynucleotide–Adenosine Nucleosidase, May Be an Efficacious Therapeutic Agent for SARS-CoV-2 Infection

Saporin, a type I ribosome-inactivating protein from soapwort plant, is a potent protein synthesis inhibitor. Catalytically, saporin is a characteristic N-glycosidase, and it depurinates a specific adenine residue from a universally conserved loop of the major ribosomal RNA (rRNA) of eukaryotic cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arslan, Idris, Akgul, Hafize, Kara, Murat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Laboratory Automation and Screening. Published by Elsevier Inc. 2021
Materias:	Mini-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940857/ https://www.ncbi.nlm.nih.gov/pubmed/33155515 http://dx.doi.org/10.1177/2472555220970911

Ejemplares similares

Structure of Klebsiella pneumoniae adenosine monophosphate nucleosidase
por: Richardson, Brian C., et al.
Publicado: (2022)

Catalytic Site Cooperativity in Dimeric Methylthioadenosine Nucleosidase
por: Wang, Shanzhi, et al.
Publicado: (2014)

Molecular docking based design of Inhibitors for viral Non-Nucleosidase as potential anti-retroviral agents
por: Alharbi, Ahmed, et al.
Publicado: (2020)

Arabidopsis thaliana nucleosidase mutants provide new insights into nucleoside degradation
por: Riegler, Heike, et al.
Publicado: (2011)

Transition state analogues of 5′-methylthioadenosine nucleosidase disrupt quorum sensing
por: Gutierrez, Jemy A., et al.
Publicado: (2009)

Evolution of the bacterial nucleosidase PpnN and its relation to the stringent response
por: Bærentsen, René Lysdal, et al.
Publicado: (2019)

The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells
por: Wensley, Harrison J., et al.
Publicado: (2021)

Therapeutic antibodies under development for SARS‐CoV‐2
por: Ma, Zetong, et al.
Publicado: (2021)

Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency
por: Castiello, Maria Carmina, et al.
Publicado: (2020)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Polynucleotide Phosphorylase Activity May Be Modulated by Metabolites in Escherichia coli
por: Nurmohamed, Salima, et al.
Publicado: (2011)

Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
por: Flavell, D. J., et al.
Publicado: (1995)

Analysis of the Sequence Preference of Saporin by Deep Sequencing
por: Hauf, Samuel, et al.
Publicado: (2022)

Enzymes of Polynucleotide Metabolism
por: King, Mary E.
Publicado: (1960)

Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2
por: Bilal, Muhammad, et al.
Publicado: (2020)

Multi-drug resistant ESKAPE pathogens and the uses of plants as their antimicrobial agents
por: Idris, Farhana Nazira, et al.
Publicado: (2023)

Actions of Adenosine on Cullin Neddylation: Implications for Inflammatory Responses
por: Curtis, Valerie F., et al.
Publicado: (2014)

Saporin-S6: A Useful Tool in Cancer Therapy
por: Polito, Letizia, et al.
Publicado: (2013)

Streptavidin-Saporin: Converting Biotinylated Materials into Targeted Toxins
por: Ancheta, Leonardo R., et al.
Publicado: (2023)

Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
por: Tazzari, P. L., et al.
Publicado: (1993)

Fast-scan Cyclic Voltammetry for the Characterization of Rapid Adenosine Release
por: Nguyen, Michael D., et al.
Publicado: (2014)

Nanoparticulate systems for polynucleotide delivery
por: Basarkar, Ashwin, et al.
Publicado: (2007)

Adenosine, Energy Metabolism, and Sleep
por: Porkka-Heiskanen, Tarja, et al.
Publicado: (2003)

Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy
por: Polito, Letizia, et al.
Publicado: (2011)

Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins
por: Giansanti, Francesco, et al.
Publicado: (2018)

New Insights on Saporin Resistance to Chemical Derivatization with Heterobifunctional Reagents
por: Bortolotti, Massimo, et al.
Publicado: (2023)

SARS-COV-2, can you be over it?
por: Fiocchi, Alessandro, et al.
Publicado: (2021)

Double-Stranded Polynucleotides as Interferon Inducers
por: Field, A. K., et al.
Publicado: (1970)

Potential therapeutic agents against COVID-19: What we know so far
por: Lu, Chih-Chia, et al.
Publicado: (2020)

SARS-CoV-2 Mutations and their Viral Variants
por: Cosar, Begum, et al.
Publicado: (2022)

John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors()
por: Jacobson, Kenneth A., et al.
Publicado: (2014)

SARS-CoV-2 (COVID-19) and the Endocrine System
por: Lundholm, Michelle D, et al.
Publicado: (2020)

The Impact of SARS-Cov-2 Virus Infection on the Endocrine System
por: Somasundaram, Noel Pratheepan, et al.
Publicado: (2020)

Thyroiditis and SARS-CoV-2 pandemic: a review
por: Caron, Philippe
Publicado: (2021)

Impact of SARS-CoV-2 infection on liver disease
por: Salgüero Fernández, Sergio, et al.
Publicado: (2022)

Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents
por: Al-Fakhrany, Omnia Momtaz, et al.
Publicado: (2023)

Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern
por: Murugadoss, Karthik, et al.
Publicado: (2022)

Adenosine Receptor Heteromers and their Integrative Role in Striatal Function
por: Ferré, Sergi, et al.
Publicado: (2007)

Prospects for mucosal vaccine: shutting the door on SARS-CoV-2
por: Mudgal, Rajat, et al.
Publicado: (2020)

Laboratory diagnosis of SARS-CoV-2: available approaches and limitations
por: Abduljalil, J.M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s557rcgmmpe5i8vrvcrusnjje8